mardi 7 mai 2013

PFE.nyse


In a move designed to take bashfulness out of the erectile dysfunction equation, drugmaker Pfizer  told the Associeted press that it will begin selling its popular pill, Viagra, directly to patients on its website.
A prescription will still be needed, but coming face to face with a pharmacist in an exchange many consider embarrassing is now a thing of the past. No longer will anxious men feel like they have to step up to the window with eight items they don’t need - including a bottle of yeast tablets, bubble gum, a magazine and a package of light bulbs – then cautiously slide their Viagra prescription across the counter, whispering, “While you’re at it, can you fill this too, please?”
Now, all that will be required is a prescription, a computer and a click of the mouse button. No fuss, no muss. And, best of all, no sense of public shame.
Other major drug makers will watch Pfizer's move closely. If it works, look for a plethora of online offerings, especially for drugs for non-urgent conditions with an embarrassment factor built in. These might include diet drugs, medicines for baldness and birth control pills.
Les Funtleyder, a health care strategist at private equity fund Poliwogg believes Pfizer's site will attract "fence-sitters" who are nervous about buying online. "If it works,” Funtleyder said, “everybody will hop on the train."
Since everyone, including men with erectile dysfunction, loves a bargain, Pfizer is rolling out the program with an attractive offer. Instead of the regular price of $25-a-pill, Pfizer is offering 3 free pills with the first order and 30 percent off the second order.
Viagra is one of Pfizer’s top drugs, with $2 billion in worldwide revenue last year. It’s also the most counterfeited drug in the U.S., according to the company. Part of the reason is the so-called “double-whammy” benefit for counterfeiters. The drug is expensive and it treats a condition that many consider embarrassing.
One important false rumor Pfizer hopes to counter with its new program is the notion that online pharmacies selling copycat Viagra claim they are selling generic forms of the drug. There is no such thing as generic Viagra. Pfizer’s patents do not expire until 2020 and until then only Pfizer can make and sell legitimate forms of the drug.
Vic Cavelli, head of marketing for primary care medicines at Pfizer, said the company plans to have drugstore chain CVS Caremark Corp.CVS.nyse fill the orders placed on viagra.com.
Edward Jones analyst, Judson Clark, is unsure about whether Pfizer’s new strategy will help counter drooping Viagra sales. He expects a 5 percent decline each year for the next five years and, while he says he thinks the plan represents a novel approach, he doesn’t know if it will provide the boost Pfizer hopes for.



EA.nasdaq



Electronic Arts Inc.  has a better friend from an old friend in the world of video games and brands. News has broken that The Walt Disney Company  and EA have entered into a new multi-year exclusive licensing agreement to develop and publish new games based on Star Wars characters and story lines.
While financial terms were not disclosed, EA is going to develop and publish new Star Wars titles on all interactive platforms and the most popular game genres Disney will retain certain rights to develop new titles within the mobile, social, tablet and online game categories.
Disney has gone out of its way to indicate that there will be many more Star Wars efforts launched other than just Episodes 7,8, and 9. We called this a multi-generational win for Disney and the EA deal only goes to show that Disney is not lightening up on its efforts here.


lundi 6 mai 2013


Le Pentagone est aujourd'hui un très gros consommateur de smartphones, avec pas moins de 600 000 appareils dans son parc. Longtemps, ce marché a été la chasse gardée de BlackBerry, et aujourd'hui plus des trois quarts des appareils en service sont issus du constructeur canadien, contre à peine 41 000 iPhone et 8700 Androphones, ces deux derniers OS n'étant pour l'instant utilisés qu'à titre expérimental.
Les choses pourraient toutefois changer à l'avenir. En effet, le Pentagone procède en ce moment à la certification de nouveaux appareils. Si les nouveaux modèles de BlackBerry sont d'ores et déjà certifiés, l'iPhone et l'iPad devraient l'être prochainement si les tests de la DISA (Defense Information Systems Agency) sont concluants, avec dans un premier temps une certification pour les usages peu sensibles, comme la gestion de mails et la navigation web.

Si l'iPhone obtient cette certification, ce sera une excellente nouvelle pour Apple, puisqu'en plus de lui ouvrir un marché potentiel de quelques centaines de milliers d'appareils, une telle certification pourrait avoir un rôle dans le marketing auprès des entreprises, en prouvant qu'iOS offre un niveau élevé de sécurité. Mais malheureusement pour Apple, elle se retrouvera à nouveau face à son plus gros concurrent, Samsung, qui lui a grillé la politesse en obtenant la certification de son petit dernier, le Galaxy S4, grâce a la suite logicielle Samsung Knox, une solution de sécurité développée par Samsung à destination des entreprises.

IPO

Insys Therapeutics, which markets an opioid and synthetic marijuana drug for cancer pain and CINV, raised $32 million by offering 4 million shares at $8, at low end of the range of $8 to $10. The company had previously filed to offer 4 million shares at a range of $16 to $18. Insys Therapeutics will list on the NASDAQ under the symbol INSY. Wells Fargo Securities and JMP Securities acted as lead managers on the deal



SUBSYS SPRAY

Subsys ® is a proprietary, single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue.


DrugIndicationPreclinicalPhase 1Phase 2/3NDAApproved
Subsys® Spray (NDA)BTCP in Opioid Tolerant Patients
Dronabinol Oral Solution (Phase 3)CINV
Dronabinol Generics
Liposomal Encapsulated Paclitaxel (Phase 2)Metastic Cancers

We are assembling a product pipeline targeting cancer-supportive care and cancer therapy that we believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization.


DrugIndicationPreclinicalPhase 1Phase 2/3NDAApproved
Fentanyl Sublingual SprayBTCP in Opioid Tolerant Patients
Dronabinol Oral Solution (Pre-NDA)CINV

dimanche 5 mai 2013

The Cube


3-D printers have officially gone mainstream. You can now get one at Staples for $1,300.

Staples says it is the first major U.S. retailer to sell a 3-D printer. It began selling The Cube, made by 3D Systems DDD.nyse., on Staples.com Friday, and the printer will hit "many" of the retailer's brick-and-mortar stores by June.
While 3-D printers have long been used in industrial manufacturing, a recent "maker" movement is slowly popularizing in-home versions of the devices.
The Cube, like other 3-D printers, is a machine that creates physical, three-dimensional objects.
http://www.3dsystems.com/

BRK.a BRK.b


Le conglomérat a donné ses résultats vendredi et quelques modifications à son porte-feuille....
Archer Daniels Midland Co. ADM.NYSE was a new position at the last report and with Buffett giving more investing money of about $1 billion to Ted Weschler and Todd Coombs lately, our bet is that this position has been added to. ADM was a new position of 5.95 million shares worth some $163.1 million as of the end of 2012.
DaVita Inc. DVA.NYSE was already more than a 10% stake and the firm keeps raising its stake. Frankly, we would not be shocked if this company was just acquired outright down the road by Berkshire Hathaway.
DirecTV DTV.NASDAQ has been added to and we see no reason that the latest stake of almost 34 million shares would not be added to yet again. The satellite TV provider is up 16% year to date, just hit a new high on Friday and is up by close to 4% since the end of the first quarter.
General Motors Co. GM.NYSE has been added to before. It is possible that Buffett is adding to the stake here, although he would likely want to buy these at a discount in the government offering of “Government Motors” stock rather than in the open market.
International Business Machines Corp. IBM.NYSE is going to likely keep growing for Berkshire Hathaway as the company keeps buying back stock and recently raised its dividend. Warren Buffett told CNBC, “I won’t be a seller of IBM.” This was over 68 million shares last quarter for a 6.03% stake, and our bet is that Buffett added a bit to it after the stock went on sale after a poor earnings report.
Johnson & Johnson JNJ.NYSE is likely to be void entirely now in the Berkshire Hathaway stock portfolio. This was a mere 327,100 shares last time and has shrunk through time. The stake is so small that it was likely just not exited right before the end of the last quarter.
Moody’s Corp. MCO.NYSE has been confirmed that the stock holding is shrinking here. Berkshire Hathaway recently sold off about 1.7 million shares of . The position is very profitable for the conglomerate despite the woes of the past for the ratings agency. Buffett’s stake is still over 26 million shares.
Precision Castparts Corp. PCP.NYSE was a larger stake last quarter at roughly 2 million shares versus being a new position of 1.25 million shares in the prior quarter. If the new portfolio managers have new funds, they may have added to this even the stock has been range-bound so far in 2013.
Berkshire Hathaway keeps adding over and over to its position of Wells Fargo & Co. WFC.NYSE and we expect that to have continued in the first quarter.